Rituximab in the treatment of anti-neutrophil cytoplasm antibody-Associated vasculitis

Nephron - Clinical Practice

Volumn 128, Issue , 2014, Pages 243-249

  Jones, Rachel B ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Anti neutrophil cytoplasm antibody Associated vasculitis; Remission; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; BODY SURFACE; CLINICAL PRACTICE; DRUG SAFETY; EOSINOPHILIC GRANULOMA; HUMAN; KIDNEY DISEASE; LUNG DISEASE; MAINTENANCE THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; IMMUNOLOGY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; RITUXIMAB;

EID: 84922921811     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000368580     Document Type: Review

References (46)

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.
2. Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D; European Vasculitis Study Group: Risk factors for relapse of anti-neutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum 2012; 64:542-548.
3. Walton EW: Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 34:265-270.
4. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
5. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gas-kin G, Gregorini G, de Groot K, Gross W, Ha-gen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculi-tis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
6. Jayne DR, Gaskin G, Rasmussen N, Abramo-wicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, West-man KW, van der Woude FJ, de Lind van Wi-jngaarden RA, Pusey CD; European Vasculi-tis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188.
7. Tedder TF, Engel P: CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15:450-454.
8. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
9. Edwards JC, Cambridge G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40:205-211.
10. Popa ER, Stegeman C, Bos NA, Kallenberg CG, Tervaert JW: Differential B-And T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103:885-894.
11. Holden NJ, Williams JM, Morgan MD, Chal-la A, Gordon J, Pepper RJ, Salama AD, Harper L, Savage CO: ANCA-stimulated neutro-phils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011; 70:2229-2233.
12. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: An-tineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulone-phritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
13. Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS: Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculi-tis in mice with a humanized immune system. PLoS One 2012; 7:e28626.
14. Voswinkel J, Müller A, Lamprecht P: Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoanti-body production. Ann NY Acad Sci 2005; 1051:12-19.
15. Voswinkel J, Müller A, Kraemer JA, Lampre-cht P, Herlyn K, Holl-Ulrich K, Feller AC, Pi-tann S, Gause A, Gross WL: B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859-864.
16. Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclo-phosphamide. J Immunol 1982; 128:2453-2457.
17. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplas-mic antibody-Associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168.
18. Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44:2836-2840.
19. Smith KG, Jones RB, Burns SM, Jayne DRW: Long-term comparison of rituximab treatment for refractory systemic lupus erythema-tosus and vasculitis. Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970-2982.
20. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187.
21. Eriksson P: Nine patients with anti-neutro-phil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540-548.
22. Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory an-tineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum 2005; 52:262-268.
23. Stasi R, Stipa E, Del Poeta G, Amadori S, New-land AC, Provan D: Long-term observations of patients with anti-neutrophil cytoplasmic antibody-Associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45: 1432-1436.
24. Lovric S, Erdbruegger U, Kümpers P, Woy-wodt A, Koenecke C, Wedemeyer H, Haller H, Haubitz M: Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-Associated vasculitis: single centre experience with 15 patients. Nephrol Dial Transplant 2009; 24; 179-185.
25. Seo P, Specks U, Keogh KA: Efficacy of ritux-imab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35:2017-2023.
26. Sánchez-Cano D, Callejas-Rubio J, Ortego-Centeno N: Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 2008; 14:92-93.
27. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K, Lamprecht P, Gross WL: Lack of efficacy of rituximab in Wegen-er's granulomatosis with refractory granulo-matous manifestations. Ann Rheum Dis 2006; 65:853-858.
28. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR: Rituximab for remission maintenance in relapsing ANCA-Associated vasculitis. Arthritis Rheum 2012; 64:3760-3769.
29. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fer-venza FC, Specks U: Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegen-er's): ten-year experience at a single center. Arthritis Rheum 2012; 64:3770-3778.
30. Azar L, Springer J, Langford CA, Hoffman GS: Rituximab with or without a conventional maintenance agent in relapsing granuloma-tosis with polyangiitis: a retrospective single-center study. Arthritis Rheumatol 2014; 66: 2862-2870.
31. Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N: Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 2013; 15:R133.
32. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC: Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26: 2865-2871.
33. Stone JH, Merkel PA, Spiera R, Seo P, Lang-ford CA, Hoffman GS, et al: Rituximab versus cyclophosphamide for ANCA-Associated vas-culitis. N Engl J Med 2010; 363:221-232.
34. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculi-tis Study Group: Rituximab versus cyclophos-phamide in ANCA-Associated renal vasculi-tis. N Engl J Med 2010; 363:211-220.
35. Specks U, Merkel PA, Seo P, Spiera R, Lang-ford CA, Hoffman GS, et al: Efficacy of remission-induction regimens for ANCA-Associat-ed vasculitis. N Engl J Med 2013; 369:417-427.
36. Jones RB, Walsh M, Jayne D: Two-year follow-up results from a randomized trial of rituximab versus cyclophosphamide for ANCA-Associated renal vasculitis: RITUXVAS. Clin Exp Immunol 2011; 164: 57.
37. Ferraro AJ, Smith SW, Neil D, Savage COS: Relapsed Wegener's granulomatosis after rituximab therapy-B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. Nephrol Dial Transplant 2008; 23:3030-3032.
38. Rhee EP, Laliberte KA, Niles JL: Rituximab as maintenance therapy for anti-neutrophil cy-toplasmic antibody-Associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-1400.
39. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, Grasland A, Zoulim A, Le Guen J, Prud'homme A, Bienvenu B, de Menthon M, Camps S, LE Guern V, Aouba A, Cohen P, Mouthon L, Guillevin L; French Vasculitis Study Group: Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39:125-130.
40. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Rav-Aud P, Mouthon L; the French Vasculitis Study Group: Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vascu-litis. N Engl J Med 2014;371:1771-1780.
41. EMA summary of product chracteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Inform ation/human/000165/WC500025821.pdf.
42. Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al: The effect of ritux-imab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 2014; 15:178.
43. Venhoff N, Effelsberg N, Salzer U, Warnatz K, Peter H, Lebrecht D, et al: Impact of ritux-imab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-Associated vas-culitides. PloS One 2012; 7:e37626.
44. Tesfa D, Palmblad J: Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011; 4:619-625.
45. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al: Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496-1502.
46. Tarella C, Passera R, Magni M, et al: Risk factors for the development of secondary malignancy after high-dose chemotherapy and au-tograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011; 29:814-824.